The pathophysiology of pulmonary hypertension in left heart disease

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 309, Issue 9, 2015, Pages L924-L941

  Breitling, Siegfried ^a,b   Ravindran, Krishnan ^a   Goldenberg, Neil M ^a,c   Kuebler, Wolfgang M ^a,c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Alveolar fluid clearance; Endothelial function; Left heart disease; Pulmonary hypertension; Vascular remodeling

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NEBIVOLOL; PROSTAGLANDIN DERIVATIVE; RIOCIGUAT; SILDENAFIL; VASOACTIVE AGENT; VASODILATOR AGENT;

CARDIOVASCULAR MORTALITY; CELL MEMBRANE PERMEABILITY; CLINICAL FEATURE; ENDOTHELIAL DYSFUNCTION; FLUID CLEARANCE; FUNCTIONAL ASSESSMENT; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE OVERLOAD; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ARTERY PRESSURE; LUNG CLEARANCE; NONHUMAN; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RABBIT MODEL; REVIEW; VASCULAR REMODELING; COMPLICATION; HEART FAILURE; HYPERTENSION, PULMONARY; LUNG ALVEOLUS; PATHOLOGY; PREVALENCE; VASCULARIZATION;

HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; PREVALENCE; PULMONARY ALVEOLI;

EID: 84946402165     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00146.2015     Document Type: Review

References (171)

1. Alvarez DF, King JA, Townsley MI. Resistance to store depletioninduced endothelial injury in rat lung after chronic heart failure. Am J Respir Crit Care Med 172: 1153–1160, 2005
2. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF. Long-term effects of darusentan on leftventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double- blind, placebo-controlled trial. Lancet 364: 347–354, 2004
3. Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin- sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 91: 7583–7587, 1994
4. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 361: 1864–1871, 2009
5. Armstrong SM, Khajoee V, Wang C, Wang T, Tigdi J, Yin J, Kuebler WM, Gillrie M, Davis SP, Ho M, Lee WL. Co-regulation of transcellular and paracellular leak across microvascular endothelium by dynamin and Rac. Am J Pathol 180: 1308–1323, 2012
6. Azzam ZS, Dumasius V, Saldias FJ, Adir Y, Sznajder JI, Factor P. Na,K-ATPase overexpression improves alveolar fluid clearance in a rat model of elevated left atrial pressure. Circulation 105: 497–501, 2002
7. Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, Yu Z, Sui A, Cheung M, Leishman E, Eidam HS, Ye G, Willette RN, Thorneloe KS, Bradshaw HB, Matalon S, Jordt SE. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 307: L158–L172, 2014
8. Bandyopadhyay D, Bajaj N, Zein J, Minai O, Dweik R. Outcomes of &6;-blocker use in pulmonary arterial hypertension: a propensity-matched analysis. Eur Respir J 46: 750–760, 2015
9. Bartelds B, Van Loon RL, Mohaupt S, Wijnberg H, Dickinson MG, Boersma B, Takens J, Van Albada M, Berger RM. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest 141: 651–660, 2012
10. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5’-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebocontrolled clinical trial. J Card Fail 14: 189–197, 2008
11. Berthiaume Y, Folkesson HG, Matthay MA. Lung edema clearance: 20 years of progress: invited review: alveolar edema fluid clearance in the injured lung. J Appl Physiol 93: 2207–2213, 2002
12. Bhattacharya J. The microphysiology of lung liquid clearance. Adv Exp Med Biol 381: 95–108, 1995
13. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise AV, Roessig L, Semigran MJ. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128: 502–511, 2013
14. Breckenridge R. Heart failure and mouse models. Dis Model Mech 3: 138–143, 2010
15. Brune K, Frank J, Schwingshackl A, Finigan J, Sidhaye VK. Pulmonary epithelial barrier function: some new players and mechanisms. Am J Physiol Lung Cell Mol Physiol 308: L731–L745, 2015
16. Bueltmann M, Kong X, Mertens M, Yin N, Yin J, Liu Z, Koster A, Kuppe H, Kuebler WM. Inhaled milrinone attenuates experimental acute lung injury. Intensive Care Med 35: 171–178, 2009
17. Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, Jiang R, Roger VL. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 59: 222–231, 2012
18. Butler J, Stankewicz MA, Wu J, Chomsky DB, Howser RL, Khadim G, Davis SF, Pierson RN, Wilson JR. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. J Heart Lung Transplant 24: 170–177, 2005
19. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134: 44–54, 1997
20. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 105: 1663–1668, 2002
21. Channick R, Badesch DB, Tapson VF, Simonneau G, Robbins I, Frost A, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo- controlled study. J Heart Lung Transplant 20: 262–263, 2001
22. Chen L, Bosworth CA, Pico T, Collawn JF, Varga K, Gao Z, Clancy JP, Fortenberry JA, Lancaster JR, Matalon S. DETANO and nitrated lipids increase chloride secretion across lung airway cells. Am J Respir Cell Mol Biol 39: 150–162, 2008
23. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, Stone GW. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 62: 1092–1100, 2013
24. Cho SH, Yao Z, Wang SW, Alban RF, Barbers RG, French SW, Oh CK. Regulation of activin A expression in mast cells and asthma: its effect on the proliferation of human airway smooth muscle cells. J Immunol 170: 4045–4052, 2003
25. Clozel M, Qiu C, Qiu CS, Hess P, Clozel JP. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 39: 142–147, 2002
26. Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, Ghofrani HA, Weissmann N, Kuebler WM, Seeger W, Grimminger F, Schermuly RT. Involvement of mast cells in monocrotaline- induced pulmonary hypertension in rats. Respir Res 12: 60, 2011
27. Davies S, Wilkinson P, Keegan J, Bailey J, Timmis A, Wedzicha J, Rudd R. Pulmonary microvascular permeability in patients with severe mitral stenosis. Heart 65: 89–93, 1991
28. Davies SW, Bailey J, Keegan J, Balcon R, Rudd RM, Lipkin DP. Reduced pulmonary microvascular permeability in severe chronic left heart failure. Am Heart J 124: 137–142, 1992
29. De Jesus Perez V, Yuan K, Alastalo TP, Spiekerkoetter E, Rabinovitch M. Targeting the Wnt signaling pathways in pulmonary arterial hypertension. Drug Discov Today 19: 1270–1276, 2014
30. De Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 184: 83–99, 2009
31. Delaney C, Gien J, Roe G, Isenberg N, Kailey J, Abman SH. Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol 304: L894–L901, 2013
32. Delgado JF, Conde E, Sánchez V, López-Ríos F, Gómez-Sánchez MA, Escribano P, Sotelo T, De La Cámara AG, Cortina J, De La Calzada CS. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 7: 1011–1016, 2005
33. Delgado JF. The right heart and pulmonary circulation (III). The pulmonary circulation in heart failure. Rev Esp Cardiol 63: 334–345, 2010
34. Denault AY, Pearl RG, Michler RE, Rao V, Tsui SS, Seitelberger R, Cromie M, Lindberg E, D’Armini AM. Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial. J Cardiothorac Vasc Anesth 27: 1212–1217, 2013
35. De Pasquale CG, Bersten AD, Doyle IR, Aylward PE, Arnolda LF. Infarct-induced chronic heart failure increases bidirectional protein movement across the alveolocapillary barrier. Am J Physiol Heart Circ Physiol 284: H2136–H2145, 2003
36. Deuchar G, Docherty A, MacLean MR, Hicks MN. Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone. Br J Pharmacol 135: 1060–1068, 2002
37. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2: 262–271, 2009
38. Ben Driss A, Devaux C, Henrion D, Duriez M, Thuillez C, Levy BI, Michel JB. Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure. Circulation 101: 2764–2770, 2000
39. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81: 1510–1515, 1996
40. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172: 1741–1748, 1990
41. Ehrlich P. Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukozyten. [Contributions to the knowledge of the granulated connective tissue cells and eosinophilic leukocytes]. Arch Anat Physiol 3: 166–169, 1879
42. Farha S, Sharp J, Asosingh K, Park M, Comhair SA, Tang WH, Thomas J, Farver C, Hsieh F, Loyd JE, Erzurum SC. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ 2: 220–228, 2012
43. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91: 391–392, 2005
44. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, Kihara Y, Kawano M, Watanabe H, Takeda Y, Adachi T, Osanai S, Tanabe N, Inoue T, Kubo A, Ota Y, Fukuda K, Nakano T, Shimokawa H. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J 77: 2619–2625, 2013
45. Fukuroda T, Kobayashi M, Ozaki S, Yano M, Miyauchi T, Onizuka M, Sugishita Y, Goto K, Nishikibe M. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol 76: 1976–1982, 1994
46. Galiè N, Simonneau G. The fifth world symposium on pulmonary hypertension. J Am Coll Cardiol 62: D1–D3, 2013
47. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37: 183–188, 2001
48. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369: 330–340, 2013
49. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182: 1171–1177, 2010
50. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214–221, 1995
51. Goodale F Jr, Sanchez G, Friedlich AL, Scannell JG, Myers GS. Correlation of pulmonary arteriolar resistance with pulmonary vascular changes in patients with mitral stenosis before and after valvulotomy. N Engl J Med 252: 979–983, 1955
52. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 7: 648–659, 2010
53. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation 126: 975–990, 2012
54. Guazzi M, Galiè N. Pulmonary hypertension in left heart disease. Eur Respir Rev 21: 338–346, 2012
55. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50: 2136–2144, 2007
56. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44: 2339–2348, 2004
57. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase- 5 inhibition in a 1-year study. Circulation 124: 164–174, 2011
58. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4: 8–17, 2011
59. Guo Y, DuVall MD, Crow JP, Matalon S. Nitric oxide inhibits Na absorption across cultured alveolar type II monolayers. Am J Physiol Lung Cell Mol Physiol 274: L369–L377, 1998
60. Guyatt GH, Devereaux PJ. A review of heart failure treatment. Mt Sinai J Med 71: 47–54, 2004
61. Haraldsson Å, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 114: 780–786, 1998
62. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 39: 60–76, 1998
63. Heath D, Trueman T, Sukonthamarn P. Pulmonary mast cells in mitral stenosis. Cardiovasc Res 3: 467–471, 1969
64. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 44: 1003–1006, 1991
65. Hentschel T, Yin N, Riad A, Habbazettl H, Weimann J, Koster A, Tschope C, Kuppe H, Kuebler WM. Inhalation of the phosphodiesterase- 3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 106: 124–131, 2007
66. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367–1373, 1993
67. Hoes A, Mosterd A. Heart failure: chapter 2. Epidemiology: prevalence, incidence, prognosis. Neth Heart J 12: 235–238, 2004
68. Hoffmann J, Yin J, Kukucka M, Yin N, Saarikko I, Sterner-Kock A, Fujii H, Leong-Poi H, Kuppe H, Schermuly RT, Kuebler WM. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J 37: 1400–1410, 2011
69. Huang W, Kingsbury MP, Turner MA, Donnelly JL, Flores NA, Sheridan DJ. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res 49: 207–217, 2001
70. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425–1436, 2004
71. Hunt JM, Bethea B, Liu X, Gandjeva A, Mammen PP, Stacher E, Gandjeva MR, Parish E, Perez M, Smith L, Graham BB, Kuebler WM, Tuder RM. Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease. Am J Physiol Lung Cell Mol Physiol 305: L725–L736, 2013
72. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Marumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92: 398–403, 1993
73. Ivey CL, Roy BJ, Townsley MI. Ablation of lung endothelial injury after pacing-induced heart failure is related to alterations in Ca2+ signaling. Am J Physiol Heart Circ Physiol 275: H844–H851, 1998
74. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45: 173–202, 2002
75. Jian MY, King JA, Al-Mehdi AB, Liedtke W, Townsley MI. High vascular pressure-induced lung injury requires P450 epoxygenase-dependent activation of TRPV4. Am J Respir Cell Mol Biol 38: 386–392, 2008
76. Kaestle SM, Reich CA, Yin N, Habazettl H, Weimann J, Kuebler WM. Nitric oxide-dependent inhibition of alveolar fluid clearance in hydrostatic lung edema. Am J Physiol Lung Cell Mol Physiol 293: L859–L869, 2007
77. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85: 195–197, 2002
78. Kennedy S, Wu J, Wadsworth RM, Lawrence CE, Maffia P. Mast cells and vascular diseases. Pharmacol Ther 138: 53–65, 2013
79. Kerem A, Yin J, Kaestle SM, Hoffmann J, Schoene AM, Singh B, Kuppe H, Borst MM, Kuebler WM. Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization. Circ Res 106: 1103–1116, 2010
80. Kim FY, Barnes EA, Ying L, Chen C, Lee L, Alvira CM, Cornfield DN. Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 308: L368–L377, 2015
81. Kingsbury MP, Huang W, Donnelly JL, Jackson E, Needham E, Turner MA, Sheridan DJ. Structural remodelling of lungs in chronic heart failure. Basic Res Cardiol 98: 295–303, 2003
82. Kisch-Wedel H, Kemming G, Meisner F, Flondor M, Kuebler WM, Bruhn S, Koehler C, Zwissler B. The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo. Intensive Care Med 29: 1574–1583, 2003
83. Kitahori K, He H, Kawata M, Cowan DB, Friehs I, Del Nido PJ, McGowan FX. Development of left ventricular diastolic dysfunction with preservation of ejection fraction during progression of infant right ventricular hypertrophy. Circ Heart Fail 2: 599–607, 2009
84. Krum H, Teerlink JR. Medical therapy for chronic heart failure. Lancet 378: 713–721, 2011
85. Kuebler WM, Uhlig U, Goldmann T, Schael G, Kerem A, Exner K, Martin C, Vollmer E, Uhlig S. Stretch activates nitric oxide production in pulmonary vascular endothelial cells in situ. Am J Respir Crit Care Med 168: 1391–1398, 2003
86. Kuebler WM, Ying X, Bhattacharya J. Pressure-induced endothelial Ca2+ oscillations in lung capillaries. Am J Physiol Lung Cell Mol Physiol 282: L917–L923, 2002
87. Kuebler WM, Ying X, Singh B, Issekutz AC, Bhattacharya J. Pressure is proinflammatory in lung venular capillaries. J Clin Invest 104: 495–502, 1999
88. Kuebler WM. The Janus-faced regulation of endothelial permeability by cyclic GMP. Am J Physiol Lung Cell Mol Physiol 301: L157–L160, 2011
89. Kuriyama S, Morio Y, Toba M, Nagaoka T, Takahashi F, Iwakami S, Seyama K, Takahashi K. Genistein attenuates hypoxic pulmonary hypertension via enhanced nitric oxide signaling and the erythropoietin system. Am J Physiol Lung Cell Mol Physiol 306: L996–L1005, 2014
90. Kutty RS, Parameshwar J, Lewis C, Catarino PA, Sudarshan CD, Jenkins DP, Dunning JJ, Tsui SS. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension. Eur J Cardiothorac Surg 43: 1237– 1242, 2013
91. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53: 1119–1126, 2009
92. Lange K, Gartzke J. F-actin-based Ca signaling-a critical comparison with the current concept of Ca signaling. J Cell Physiol 209: 270–287, 2006
93. Lee YS. Electron microscopic studies on the alveolar-capillary barrier in the patients of chronic pulmonary edema. Jpn Circ J 43: 945–954, 1979
94. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 106: 284–286, 2010
95. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115: 59–66, 2007
96. Loh E, Stamler JS, Hare JM, Loscalzo J, Colucci WS. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 90: 2780–2785, 1994
97. MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension-from bench to bedside? Curr Opin Pharmacol 9: 281–286, 2009
98. Marks RM, Roche WR, Czerniecki M, Penny R, Nelson DS. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab Invest 55: 289–294, 1986
99. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 60: 1455–1469, 2012
100. Matsumoto H, Suzuki N, Onda H, Fujino M. Abundance of endothelin- 3 in rat intestine, pituitary gland and brain. Biochem Biophys Res Commun 164: 74–80, 1989
101. Matthay M, Folkesson H, Verkman A. Salt and water transport across alveolar and distal airway epithelia in the adult lung. Am J Physiol Lung Cell Mol Physiol 270: L487–L503, 1996
102. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O’Connor CM, Parker JD, Torre- Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298: 2009–2019, 2007
103. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med 362: 228–238, 2010
104. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279–367, 2006
105. Mehta D, Ravindran K, Kuebler WM. Novel regulators of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 307: L924–L935, 2014
106. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109–142, 1991
107. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 102: 1718–1723, 2000
108. Morty RE, Kuebler WM. TRPV4: an exciting new target to promote alveolocapillary barrier function. Am J Physiol Lung Cell Mol Physiol 307: L817–L821, 2014
109. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137: 1187–1194, 2002
110. Mylona P, Cleland JGF. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Fail 1: 197–200, 1999
111. Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 41: 217–223, 2013
112. Naeije R. Physiology of the pulmonary circulation and the right heart. Curr Hypertens Rep 15: 623–631, 2013
113. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171: 494–499, 2005
114. Nakos G, Pneumatikos J, Tsangaris I, Tellis C, Lekka M. Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am J Respir Crit Care Med 155: 945–951, 1997
115. Natori S, Hasebe N, Jin YT, Matsusaka T, Ido A, Matsuhashi H, Ihara T, Kikuchi K. Inhaled nitric oxide modifies left ventricular diastolic stress in the presence of vasoactive agents in heart failure. Am J Respir Crit Care Med 167: 895–901, 2003
116. Okumura K, Kato H, Honjo O, Breitling S, Kuebler WM, Sun M, Friedberg MK. Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. J Mol Med 93: 663–674, 2015
117. Olschewski H, Olschewski A, Rose F, Schermuly R, Schütte H, Weissmann N, Seeger W, Grimminger F. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 138: 287–297, 2001
118. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69: 1088–1096, 1991
119. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468–1475, 1991
120. Parker JC, Ivey CL. Isoproterenol attenuates high vascular pressureinduced permeability increases in isolated rat lungs. J Appl Physiol 83: 1962–1967, 1997
121. Patten RD, Hall-Porter MR. Small animal models of heart failure development of novel therapies, past and present. Circ Heart Fail 2: 138–144, 2009
122. Penumatsa KC, Fanburg BL. Transglutaminase 2-mediated serotonylation in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 306: L309–L315, 2014
123. Perros F, Ranchoux B, Izikki M, Bentebbal S, Happé C, Antigny F, Jourdon P, Dorfmüller P, Lecerf F, Fadel E, Simonneau G, Humbert M, Bogaard H, Eddahibi S. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol 65: 668–680, 2015
124. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 9: 1196–1204, 1995
125. Porter TR, Taylor DO, Cycan A, Fields J, Bagley CW, Pandian NG, Mohanty PK. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 22: 1418–1424, 1993
126. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309: 1268–1277, 2013
127. Rich S. Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6–10,1998. Geneva: World Health Organization, 1998
128. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 88: 8277–8281, 1991
129. Rosenkranz S, Bonderman D, Buerke M, Felgendreher R, Ten Freyhaus H, Grünig E, De Haan F, Hammerstingl C, Harreuter A, Hohenforst-Schmidt W, Kindermann I, Kindermann M, Kleber FX, Kuckeland M, Kuebler WM, Mertens D, Mitrovic V, Opitz C, Schmeisser A, Schulz U, Speich R, Zeh W, Weil J. Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154, Suppl 1: S34–S44, 2011
130. Rubin L. The beta-adrenergic receptor in pulmonary arterial hypertension: a novel therapeutic target? J Am Coll Cardiol 65: 681–683, 2015
131. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903, 2002
132. Sablotzki A, Hentschel T, Gruenig E, Schubert S, Friedrich I, Mühling J, Dehne MG, Czeslick E. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 22: 746–752, 2002
133. Saldías FJ, Azzam ZS, Ridge KM, Yeldandi A, Rutschman DH, Schraufnagel D, Sznajder JI. Alveolar fluid reabsorption is impaired by increased left atrial pressures in rats. Am J Physiol Lung Cell Mol Physiol 281: L591–L597, 2001
134. Sandoval R, Malik AB, Minshall RD, Kouklis P, Ellis CA, Tiruppathi C. Ca2+ signalling and PKC activate increased endothelial permeability by disassembly of VE-cadherin junctions. J Physiol 533: 433–445, 2001
135. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10: 6, 2009
136. Schamarin P. About the Kitajew reflex. Mechanism of mitral valve vitium compensation. Ter Arch 24: 79–85, 1952
137. Scott D, Tan Y, Shandas R, Stenmark KR, Tan W. High pulsatility flow stimulates smooth muscle cell hypertrophy and contractile protein expression. Am J Physiol Lung Cell Mol Physiol 304: L70–L81, 2013
138. Seo B, Oemar BS, Siebenmann R, von Segesser L, Lüscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89: 1203–1208, 1994
139. Shichiri M, Kato H, Marumo F, Hirata Y. Endothelin-1 as an autocrine/ paracrine apoptosis survival factor for endothelial cells. Hypertension 30: 1198–1203, 1997
140. Simonneau G, D’Armini A, Ghofrani H, Grimminger F, Hoeper M, Jansa P, Kim N, Wang C, Wilkins M, Fritsch A, Davie N, Colorado P, Mayer E. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 45: 1293–1302, 2015
141. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43, Suppl S: 5S–12S, 2004
142. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62, Suppl 25: D34–D41, 2013
143. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott G, Gaine SP, Gladwin MT, Jing Z, Krowka MJ, Langleben D, Nakanishi N. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54, Suppl 1: S43–S54, 2009
144. Solymosi EA, Kaestle-Gembardt SM, Vadász I, Wang L, Neye N, Chupin CJA, Rozowsky S, Ruehl R, Tabuchi A, Schulz H, Kapus A, Morty RE, Kuebler WM. Chloride transport-driven alveolar fluid secretion is a major contributor to cardiogenic lung edema. Proc Natl Acad Sci USA 110: E2308–E2316, 2013
145. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89: 2035–2040, 1994
146. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol 19: 312–326, 1896
147. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38: 923–931, 2001
148. Tadano K, Hosokawa A, Fukuroda T, Nishikibe M. The functional shift of endothelin receptor subtypes in dogs with heart failure produced by rapid ventricular pacing. J Cardiovasc Pharmacol 44, Suppl 1: S350–S353, 2004
149. Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Matasic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, Larkin J, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ, Willette RN. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med 4: 159ra148, 2012
150. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10: 4–18, 2012
151. Townsley MI, Fu Z, Mathieu-Costello O, West JB. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res 77: 317–325, 1995
152. Tsujimura T, Hirota S, Nomura S, Niwa Y, Yamazaki M, Tono T, Morii E, Kim HM, Kondo K, Nishimune Y. Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. Blood 78: 1942–1946, 1991
153. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 23: 1427–1433, 1994
154. Tucker A, McMurtry IF, Alexander AF, Reeves JT, Grover RF. Lung mast cell density and distribution in chronically hypoxic animals. J Appl Physiol 42: 174–178, 1977
155. Uhlig S, Yang Y, Waade J, Wittenberg C, Babendreyer A, Kuebler WM. Differential regulation of lung endothelial permeability in vitro and in situ. Cell Physiol Biochem 34: 1–19, 2014
156. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann NY Acad Sci 1123: 134–145, 2008
157. Wang C, Wang J, Zhao L, Wang Y, Liu J, Shi L, Xu M. Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry. J Pharm Sci 108: 71–78, 2008
158. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90: 1410–1422, 1994
159. West JB, Tsukimoto K, Mathieu-Costello O, Prediletto R. Stress failure in pulmonary capillaries. J Appl Physiol 70: 1731–1742, 1991
160. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172: 105–113, 2005
161. Wood P. An appreciation of mitral stenosis. I. Clinical features. Br Med J 1: 1051–1063; contd, 1954
162. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, Thunnissen FB, Farver C, Hazen SL, Jennings C, Dweik RA, Arroliga AC, Erzurum SC. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18: 1746–1748, 2004
163. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415, 1988
164. Yin J, Hoffmann J, Kaestle SM, Neye N, Wang L, Baeurle J, Liedtke W, Wu S, Kuppe H, Pries AR, Kuebler WM. Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. Circ Res 102: 966–974, 2008
165. Yin J, Kuebler WM. Mechanotransduction by TRP channels: general concepts and specific role in the vasculature. Cell Biochem Biophys 56: 1–18, 2010
166. Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 4: 198–206, 2011
167. Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, Kuppe H, Kuebler WM. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med 37: 980–986, 2009
168. Yip HK, Wu CJ, Chang HW, Yang CH, Yu TH, Chen YH, Hang CL. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 127: 1491–1497, 2005
169. Yu XM, Wang L, Li JF, Liu J, Li J, Wang W, Wang J, Wang C. Wnt5a inhibits hypoxia-induced pulmonary arterial smooth muscle cell proliferation by downregulation of &6;-catenin. Am J Physiol Lung Cell Mol Physiol 304: L103–L111, 2013
170. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 50: 320–324, 1982
171. Zhou Z, de Beer VJ, de Wijs-Meijler D, Bender SB, Hoekstra M, Laughlin MH, Duncker DJ, Merkus D. Pulmonary vasoconstrictor influence of endothelin in exercising swine depends critically on phosphodiesterase 5- activity. Am J Physiol Lung Cell Mol Physiol 306: L442–L452, 2014.